TY - JOUR
T1 - BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland
T2 - A population-based study
AU - Rafnar, Thorunn
AU - Benediktsdottir, Kristrun R.
AU - Eldon, Bjarki J.
AU - Gestsson, Thorgeir
AU - Saemundsson, Hafsteinn
AU - Olafsson, Karl
AU - Salvarsdottir, Anna
AU - Steingrimsson, Eirikur
AU - Thorlacius, Steinunn
N1 - Funding Information:
This project was funded by Iceland Genomics Corporation.
PY - 2004/12
Y1 - 2004/12
N2 - A single founder mutation in each of the BRCA genes has been identified in Iceland. The frequency of the BRCA1 G5193A and BRCA2 999del5 mutations in all ovarian cancer patients diagnosed over the period 1991-2000 was determined. Mutation status was correlated with family history, tumour morphology and age at diagnosis. Samples from 86% of cases (179 carcinomas and 74 borderline tumours) were available. In the carcinomas, BRCA1 and BRCA2 mutations were present in 1.2% and 6% of cases, respectively. No BRCA mutations were found in the borderline tumours. Odds Ratio (OR) of developing ovarian cancer was 20.65 for BRCA2 carriers. Family history of breast/ovarian cancer was present for 70% of BRCA2 carriers and approximately 14% for non-carriers with carcinoma. In conclusion, BRCA2 999del5 is present in 6% of ovarian cancer cases in Iceland and is associated with a 20-fold increase in the risk of the disease. The BRCA1 G5193A mutation is too rare to contribute significantly to ovarian cancer in Iceland.
AB - A single founder mutation in each of the BRCA genes has been identified in Iceland. The frequency of the BRCA1 G5193A and BRCA2 999del5 mutations in all ovarian cancer patients diagnosed over the period 1991-2000 was determined. Mutation status was correlated with family history, tumour morphology and age at diagnosis. Samples from 86% of cases (179 carcinomas and 74 borderline tumours) were available. In the carcinomas, BRCA1 and BRCA2 mutations were present in 1.2% and 6% of cases, respectively. No BRCA mutations were found in the borderline tumours. Odds Ratio (OR) of developing ovarian cancer was 20.65 for BRCA2 carriers. Family history of breast/ovarian cancer was present for 70% of BRCA2 carriers and approximately 14% for non-carriers with carcinoma. In conclusion, BRCA2 999del5 is present in 6% of ovarian cancer cases in Iceland and is associated with a 20-fold increase in the risk of the disease. The BRCA1 G5193A mutation is too rare to contribute significantly to ovarian cancer in Iceland.
KW - BRCA1 G5193A
KW - BRCA2 999del5
KW - Family history
KW - Iceland
KW - Ovarian cancer
KW - Population-based
UR - http://www.scopus.com/inward/record.url?scp=9644257250&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2004.09.008
DO - 10.1016/j.ejca.2004.09.008
M3 - Article
C2 - 15571962
AN - SCOPUS:9644257250
SN - 0959-8049
VL - 40
SP - 2788
EP - 2793
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 18
ER -